Abstract
Background:
Kaposi sarcoma-associated herpes virus (KSHV) is one of the most common causal agents of Kaposi Sarcoma (KS) in individuals with HIV-infections. The virus has gained attention over the past few decades due to its remarkable pathogenic mechanisms. A group of genes, ORF71, ORF72, and ORF73, are expressed as polycistronic mRNAs and the functions of ORF71 and ORF72 in KSHV are already reported in the literature. However, the function of ORF73 has remained a mystery. The aim of this study is to conduct comprehensive exploratory experiments to clarify the role of ORF73 in KSHV pathology and discover markers of AIDS-associated KSHV-induced KS by bioinformatic approaches.
Methods and Results:
We searched for homologues of ORF-73 and attempted to predict protein-protein interactions (PPI) based on GeneCards and UniProtKB, utilizing Position-Specific Iterated BLAST (PSI-BLAST). We applied Gene Ontology (GO) and KEGG pathway analyses to identify highly conserved regions between ORF-73 and p53to help us identify potential markers with predominant hits and interactions in the KEGG pathway associated with host apoptosis and cell arrest. The protein p53 is selected because it is an important tumor suppressor antigen. To identify the potential roles of the candidate markers at the molecular level, we used PSIPRED keeping the conserved domains as the major parameters to predict secondary structures. We based the FUGE interpretation consolidations of the sequence-structure comparisons on distance homology, where the score for the amino acids matching the insertion/deletion (indels) detected were based on structures compared to the FUGE database of structural profiles. We also calculated the compatibility scores of sequence alignments accordingly. Based on the PSI-BLAST homologues, we checked the disordered structures predicted using PSI-Pred and DISO-Pred for developing a hidden Markov model (HMM). We further applied these HMMs models based on the alignment of constructed 3D models between the known structure and the HMM of our sequence. Moreover, stable homology and structurally conserved domains confirmed that ORF-73 maybe an important prognostic marker for AIDS-associated KS.
Conclusion:
Collectively, similar variants of ORF-73 markers involved in the immune response may interact with targeted host proteins as predicted by our computational analysis. This work also suggests the existence of potential conformational changes that need to be further explored to help elucidate the role of immune signaling during KS towards the development of therapeutic applications.
Introduction
Pre-existing human immunodeficiency virus (HIV) infections affect the immune system increasing the risk for development of Kaposi sarcoma (KS). Since the discovery of Kaposi sarcoma-associated herpesvirus (KSHV), also termed human herpesvirus 8 (HHV8), the tumor development and oncogenesis were associated with co-expression of different genes (Barré-Sinoussi et al., 1983; Gelmann et al., 1983). KS is a common type of cancer associated with blood vessels and lymph nodes. Soon after the discovery of HIV-1, scientists discovered γ-herpesvirus in KS lesions (Chang et al., 1994). Now that the full KSHV genome has been sequenced, it fulfils Koch's modern postulates linking the KS cancer initiation to the oncogenic virus (Russo et al., 1996; zur Hausen, 2001). KSHV is a key viral pathogen in cancer biology affecting humans and its discovery promoted clinical and epidemiological research into viral oncology (Chang et al., 1994). However, many questions remain unanswered due to the significant mortality and rapid morbidity of those affected by HIV-1 and KSHV (Parkin, 2006; Sinfield et al., 2007; Dittmer and Damania, 2019; Gaur et al., 2019).
In fact, KS was named after Dr. Moritz Kaposi, a prominent Hungarian dermatologist, who described KS as an ‘idiopathic pigmented sarcoma of the skin' in 1872 (Kaposi, 1872). The evolved gamma-herpesviruses have been classified into many subfamilies (Roizman et al., 1981) and produce many viral gene products capable of subverting the normal cellular machinery through processes involving apoptosis, cell cycle progression, antiviral responses, and immune surveillance resulting in alterations in master cell signaling pathways to establish a persistent host infection. The double-stranded KSHV genome (124–174 kb) is enclosed in an icosahedral capsid composed of 162 capsomeres with many of its ORFs being conserved in alpha- and beta-herpesviruses, but absent from other herpesviruses.
The KSHV is closely related to the subfamily Rhadinoviridae (gamma-2-herpesviruses), which is also close to the Herpes virus saimiri (HVS); therefore, similarities between ORFs of KSHV and HVS may influence the pathogenesis of KS (Schäfer et al., 2003). The HVS genome exists as a stable non-integrated circular episome in altered human and simian T cells. A group of genes, ORF71, ORF72, and ORF73, are located at the right end of the L-DNA and are expressed as polycistronic mRNAs (Fickenscher et al., 1996). Initial studies discerned that both KSHV and HVS ORF71 encode the anti-apoptotic FLICE inhibitory protein (vFLIP) (Thome et al., 1997), although HVS ORF71 is not mandatory for viral replication, transformation, or pathogenicity (Glykofrydes et al., 2000). ORF72 produces a v-Cyclin D homolog which is important for transformation of human T lymphocytes (Ensser et al., 2001). However, the function of ORF73 has remained a mystery. Therefore, developing and conducting comprehensive exploratory experiments to clarify the role of ORF73 in KSHV pathology is important.
Typically, the phenotypic features of KS initially appear on the face, legs, or feet as painless red spots but, in severe cases, the lesions also appear in the lungs and digestive tract (Bhutani et al., 2015; Yarchoan et al., 2015). KSHV is considered an oncogenic human virus (Martin et al., 1998). People with weak immune systems are more susceptible to HHV-8 infection (triggering KS development). Even with the availability of the anti-retroviral treatment [HAART], the prevalence of AIDS-associated KS has not declined significantly (Nguyen et al., 2008). Although KSHV infection is important for the onset of KS, additional factors must be present to allow the establishment of the lesions. The chance of infection is one in 100,000 among the general population, but only around one in 20 among HIV-infected individuals (La Ferla et al., 2013). The chance of acquiring the infection was one in three among HIV-infected individuals before the introduction of HAART (Beral et al., 1990; Gallo, 1998). Epidemiological observations from incidence rates in endemic areas suggest that HIV-negative individuals with KSHV infections never develop KS due to the role of immunological host factors including immune-response genes and genetic polymorphisms of the inflammatory modulators (Cottoni et al., 2004; Gazouli et al., 2004; Dorak et al., 2005).
KSHV infection of endothelial and/or hematopoietic progenitors (Della Bella et al., 2008) alter their morphology (Moses et al., 1999), growth rate, gene expression (Flore et al., 1998; Ciufo et al., 2001), and glucose metabolism (Delgado et al., 2010), leading to development of KS. Antibody titers specific for KSHV correlate with its viral load. Among individuals with low viral load, antibody titer concentrations may be too low for current serological assays to identify them. Identification of circulating biomarkers in KSHV-associated disease may help in predicting clinical outcomes (Aka et al., 2015). Immune modulatory and evasion proteins of KSHV modulate cellular responses associated with complement activation, autophagy, IFN family signaling, chemokines, natural killer cells, and apoptosis (Liang et al., 2008). They are located in a region of the viral capsid that is rich in a protein known as tegument. Six tegument proteins have been identified: ORF21, ORF33, ORF45, ORF63, ORF64, ORF73 and ORF75. Among these, the roles of ORF63 and ORF64 in immune evasion have been elucidated (Zhu et al., 2005; Gregory et al., 2011). We focused on the identification of the role of ORF73 in KSHV. The ORF73 gene encodes the HHV-LANA1 viral proteins that have been linked with AIDS-associated KS, indicating an association between HIV and ORF73. For our computational study, we hypothesized that ORF-73 is a viral proliferation factor based on studies on KS and on its interactions with the host gene p53 (Woodberry et al., 2005). The importance of ORF-73 for cellular host apoptosis through the p53 signaling pathway and p53 is in order of ORF-73 which illustrates the molecular mechanism of this key biomarker associated with KS (Duus et al., 2004).
The variability in KS lesions observed in histopathological assays include spindle cell hemangiomas, cutaneous angiosarcomas, vascular leiomyomas, and fibrous histiocytomas (Hunt et al., 2004). Endothelial biomarkers, such as CD31 and CD34, bcl-2, c-kit, Ki-67, and p53, have been used to distinguish nonvascular spindle sarcomas from angiosarcomas (Weeden, 2002; Fukunaga, 2005). Hence, investigating the HHV-latent associated nuclear antigen-1 (LANA-1) viral protein encoded by ORF-73 is important to identify markers for AIDS-associated KS. Also, studying its interactions may help in the development of preventive strategies and therapeutic options against KS. In this study, we used advanced bioinformatics tools and approaches to identify KS markers Supplementary Figure 1.
Materials and Methods
Selection of Markers
We used publicly available databases including the National Centre for Biotechnology Information (NCBI), GeneCards (Hou et al., 2017) and UniProtKB (Tang et al., 2013) to identify potential markers of KS and selected the most specific ones using “Kaposi's sarcoma” as a keyword. Human protein markers were further ran through a BLAST search for homology sequences. We extracted ORF-73 sequences from the NCBI database search using the accession number AAC57158.1. These are the exact URLs of the searched databases we used to identify markers associated with KS : GeneCards https://genecards.weizmann.ac.il/v3/index.php?path=/Search/keyword/kaposi%20sarcoma%20markers/0/20; UniPortKB https://www.uniprot.org/uniprot/?query=kaposi+sarcoma&sort=score; and NCBI https://www.ncbi.nlm.nih.gov/protein/?term=ORF-73%20kaposi%20sarcoma).
Bioinformatics: Sequence Computational Analysis
We used publicly available internet-based protein search tools and bioinformatics programs with default settings, unless otherwise stated in the text, for the analysis. We tested selected protein sequences to identify conserved domains from NCBI and BLAST algorithms, and we used the PSIPRED program to predict the secondary structure of proteins based on the conserved domain sequences. We further executed a position specific iterative BLAST (PSI-BLAST) search to build a PSSMs (position specific score matrix), which could predict the secondary structure of the input sequences (Majerciak et al., 2015) to predict secondary structures of the selected conserved domains based on multiple sequence alignment related proteins spanning a variety of organisms to reveal sequence regions containing the same, or similar, patterns of amino acids. We submitted the primary sequence of ORF-73 to FUGUE to show the sequence-structural homology by identifying distant sequence-structure homologues and alignments comparing amino acid insertions/deletions (Shi et al., 2001). We used BLASTp and PSI-BLAST (non-redundant protein databases) for pattern specific profiling (Bujnicki and Rychlewski, 2001).
Gene Ontology and Pathway Enrichment Analysis
We chose the ORF-73 target effector to perform a Gene Ontology (GO) search, is a hierarchical graph-based annotation system where the terms closer to the root describe more general information while those away from the root provide more specific information about a given GO category and all the GO terms associated with a protein sequence were obtained from the GO database. The KEGG network pathway enrichment analysis by collecting data of related genomes and their pathways associated with diseases (Yan et al., 2013) and we set a P value <0.05 as the cut-off criterion.
Protein–Protein Interaction (PPI) Network Analysis
We used the online Search Tool for the Retrieval of Interacting Genes (STRING) (Franceschini et al., 2013) and GeneMania (https://genemania.org/) to analyze interactions associated with KS among the proteins encoded by the DEGs. The two parts of GeneMania algorithm consists of an algorithm based on linear regression to calculate functional association from multiple networks from different data sources; and a label predicting gene function of composite network. We employed keywords such as—ORF73 to determine interacting partners. This was pursued using downstream regulator p53 as an apoptosis marker during pathogenesis in the host. Moreover, the marker protein was used for transient interaction study.
PPI Biochemical Analysis
We immobilized His-tag, GST-tag, or biotin-tag bait proteins to an affinity resin and incubated them with solution expressed proteins as prey proteins. We then captured the bound bait and pulled down the cell lysate flow through. Subsequently, we used mass spectrometry (MS) or Western blots to confirm interactions. Using this technique, we determined interacting protein partners of relevant proteins (Einarson, 2001; Arifuzzaman et al., 2006).
Results
Homology Search and KS Marker Identification
Annotations used to search for the KS-associated markers in the UniProtKB database quoted about 137 entries, which we then screened to find those with computationally annotated data. Search engine GeneCards reported about 369 KS markers with a relevance score. Table 1 lists the markers with the top ten scores.
Table 1
| GeneCard database | ||||
|---|---|---|---|---|
| Sl. No | Symbol | Description | GC id | Score |
| 1 | KRT15 | Keratin 15 | GC17M039675 | 1.58 |
| 2 | OSM | Oncostatin M | GC22M030658 | 1.58 |
| 3 | TAT | Tyrosine aminotransferase | GC16M071599 | 1.27 |
| 4 | MKI67 | Marker of proliferation Ki-67 | GC10M129894 | 1.14 |
| 5 | CD34 | CD34 molecule | GC01M208057 | 1.11 |
| 6 | PTX3 | Pentraxin 3, long | GC03P157154 | 1.09 |
| 7 | PECAM1 | Platelet/endothelial cell adhesion molecule 1 | GC17M062399 | 1.01 |
| 8 | FLI1 | Fli-1 proto-oncogene, ETS transcription factor | GC11P128596 | 1.01 |
| 9 | IFNA2 | Interferon, alpha 2 | GC09M021374 | 1.01 |
| 10 | ACTC1 | Actin, alpha, cardiac muscle 1 | GC15M035080 | 0.99 |
| Uniport KB database | ||||
| Sl. No. | Entry name | Protein name | Entry | Gen name |
| 1 | MIR1_HHV8P | E3 ubiquitin-protein ligase MIR1 | P90495 | K3 |
| 2 | MIR2_HHV8P | E3 ubiquitin-protein ligase MIR2 | P90489 | K5 |
| 3 | GB_HHV8P | Envelope glycoprotein B | F5HB81 | gBORF8 |
| 4 | ARBH_HHV8P | Apoptosis regulator Bcl-2 homolog | F5HGJ3 | vBCL2 ORF16 |
| 5 | SCAF_HHV8P | Capsid scaffolding protein | Q2HRB6 | ORF17 |
| 6 | OX2V_HHV8P | OX-2 membrane glycoprotein homolog | P0C788 | K14 |
| 7 | GN_HHV8P | Envelope glycoprotein N | F5HFQ0 | gN ORF53 |
| 8 | GM_HHV8P | Envelope glycoprotein M | F5HDD0 | gM ORF39 |
| 9 | ORF45_HHV8P | Protein ORF45 | F5HDE4 | ORF45 |
| 10 | VMI2_HHV8P | Viral macrophage inflammatory protein | Q98157 | ORF K4 |
| 11 | VIRF1_HHV8P | VIRF-1 | F5HF68 | vIRF-1 |
| 12 | ICP27_HHV8P | mRNA export factor ICP27 homolog | Q2HR75 | ORF57 |
| 13 | GH_HHV8P | Envelope glycoprotein H | F5HAK9 | gH ORF22 |
| 14 | AN_HHV8P | Shutoff alkaline exonuclease | Q2HR95 | ORF37 |
| 15 | LANA1_HHV8P | Protein LANA1 | Q9QR71 | LANA1 ORF73 |
GeneCards and UniPortKB databases used to choose the top-most scored identities of markers associated with KS.
We found61 ORF-73 marker homologous hits related to the family of human gamma herpes virus 8 with varied E-values. Out of these, we used only the most identical sequence (based on sequence identity was measured by matched by dividing the length of region aligned match), AAC57158.1, for our computational analyses. A search for proteins similar to the selected marker ORF-73 resulted in8 protein accessions (ORF21, ORF33, ORF45, ORF63, ORF64, and ORF75), and 2 CDS regions (accession numbers AAC57158.1 and AAC55944.1).
Domain Prediction and Structural Profile
We looked for conserved domains in the marker protein ORF-73 based on hypothetical domain sequences using literature recapitulation NCBI's Conserve Domain Database (CDD). To identify potential marker roles at the molecular level, we focused on its predicted secondary structure. Therefore, we searched for hypothetical protein having conserved domain and used accession number AAC5744 of gi.1633572 in an NCBI domain search and found only one significant hypothetical conserved domain (PHA03169) with the same accessison number (Figure 1). We then used PSIPRED to predict the secondary structure, noted the conserved domains (Figure 2) and highlighted the regions with different markers to predict the secondary structures. FUGE interpretation consolidations of the sequence-structure comparison were based on distance homology, where the score for the amino acids matching the insertion/deletion (indels) detected were based on structures compared to the FUGE database of structural profiles and we calculated the compatibility scores of sequence alignment accordingly (Table 2).
Figure 1
Figure 2
Table 2
| Sl. No. | Profile Hit | PLEN | RAWS | RVN | ZSCORE |
|---|---|---|---|---|---|
| 1 | hs4blga | 121 | −755 | 247 | 24.21 |
| 2 | hs2ap3a | 191 | 215 | 8 | 17.29 |
| 3 | hs2qiha | 136 | −822 | 10 | 16.57 |
| 4 | hs2p03a | 323 | 249 | 21 | 14.78 |
| 5 | hs1i4da | 188 | 157 | 33 | 14.61 |
| 6 | hs4cgka | 351 | 325 | 115 | 13.67 |
| 7 | hs2eqbb | 93 | −880 | 5 | 13.53 |
| 8 | hs1fxka | 103 | 168 | 19 | 13.45 |
| 9 | hs1owaa | 156 | 166 | 6 | 13.28 |
| 10 | hs4hpqc | 396 | −555 | 5 | 12.92 |
Structure of Kaposi sarcoma marker ORF-73 predicted based on an environmental-specific substitution table and its structure-dependent gap penalties.
PLEN, Profile length; RAWS, Raw alignment score; RVN, (Raw score)-(Raw score for NULL model); ZSCORE, Z-score normalized by sequence divergence (evolutionary relationship associated with a score >5.0 to the sequences are compared to each other); ZORI, Original Z-score (before normalization).
Using PSI-BLAST, we confined the search of HHV-latency-associated nuclear antigen homology to ORF-73 homologs. The DNA binding of viral protein associated with HHV-8 LANA sheltered 134 residues covering 12% of the sequence with 100% confidence based on the single highest scoring template of c4k2jB (Figures 3 and 4). 598 residues covering 51% could be modelled at >90% confidence using multiple-templates. We submitted the top-ranking model of the protein (c4k2jB, 100.0% confidence) to the 3DLigandSite (Wass et al., 2010) server to predict potential binding sites. Based on PSI-BLAST homologues, the predicted disordered structures were checked using PSI-Pred (Jones, 1999) and DISO-Pred (Jones and Cozzetto, 2015) for generating a hidden Markov model (HMM). The models were based on the alignment of the constructed 3D models between the known structure and the HMM of our sequence predicting the3-states—α-helix, β-strand or coil (“SS” indicates the predicted confidence; middle orange, yellow, and green indicate the confidence of prediction).
Figure 3
Figure 4
Gene Expression and Pathway Prediction
The exclusive over-expression of HHV-8 LANA-1 in KS confirms significant sensitivity and specificity. The domain is conserved in the HHV-8 and ORF-73, suggesting its expression during viral latency and allowing it to interact with p53, thereby inducing the apoptosis pathway. The evidence from another study indicates abnormal expression of p53 in the nodular region and metastatic lesion of angiosarcomas (rather than in the primary lesion) (Yee-Lin et al., 2018). To account for this, the lead p53 in KS was taken with reference to the database for a herpes virus-associated infection model so as to understand the immune evasion with a detailed pathway demonstrating the dominant role of a p53 oncogene in KSHV- (Figure 5). The tumor suppressor antigen p53 depends on cellular conditions inducing arrest of the cell growth and controlling cell division. This process inhibits cyclin-dependent kinases mediated by the expression of BAX and FAS antigens or by the repression of the Bcl-2expression (Kanashiro et al., 2003). Addressing the markers involved in the cell-cycle arrest is important to understand the molecular evolution of KS and for work towards its eradication. We examined PPIs to explore the complex biochemical interactions and molecular functions of proteins of interest with cellular components, as reported in Table 3. Table 3 also presents the functional enrichment of p53 including its biological process, molecular functions, and cellular components. The effector p53 is directly involved in the arrest of the G1/S cell-cycle progression from normal to cancerous cells (Chen, 2016). Analysis of PPI with STRING showed an enriched p-value of 1.31e−05 with respect to the network having significantly more interactions than expected with 11 nodes, 47 edges, an average node degree of 8.55 and an average local cluster coefficient of 0.919 (Figure 6). The functions of the protein p53, a tumor protein, are associated with various expression levels during oncogenesis. GeneMania predicted various valuable functions of the query protein and interacting partners associated with it (Figure 7).
Figure 5
Table 3
| Biological process (GO) | ||||
|---|---|---|---|---|
| Sl. No | GO-term | Description | Count in gene set | False discovery rate |
| 1 | GO:0016579 | Protein deubiquitination | 10 of 275 | 3.83e−15 |
| 2 | GO:0007249 | I-kappaB kinase/NF-kappaB signaling | 8 of 70 | 3.83e−15 |
| 3 | GO:0035666 | TRIF-dependent toll-like receptor signaling pathway | 6 of 24 | 8.43e−13 |
| 4 | GO:0051092 | Positive regulation of NF-kappaB transcription factor activity | 5 of 2142 | 6.64e−11 |
| 5 | GO:0070423 | Nucleotide-binding oligomerization domain | 5 of 27 | 4.65e−10 |
| Molecular function (GO) | ||||
| 1 | GO:0031625 | Ubiquitin protein ligase binding | 5 of 311 | 4.44e−05 |
| 2 | GO:0042975 | Peroxisome proliferator activated receptor binding | 2 of 10 | 0.00062 |
| 3 | GO:0019899 | Enzyme binding | 7 of 2197 | 0.0012 |
| 4 | GO:0042802 | Identical protein binding | 6 of 1754 | 0.0032 |
| 5 | GO:0032813 | Tumor necrosis factor receptor superfamily binding | 2 of 46 | 0.0052 |
| Cellular components (GO) | ||||
| 1 | GO:0043657 | Host cell | 4 of 29 | 2.76e−07 |
| 2 | GO:0030666 | Endocytic vesicle membrane | 5 of 152 | 2.90e−07 |
| 3 | GO:0098805 | Whole membrane | 8 of 1554 | 3.85e−06 |
| 4 | GO:0012506 | Vesicle membrane | 6 of 743 | 1.69e−05 |
| 5 | GO:0005741 | Mitochondrial outer membrane | 4 of 181 | 3.05e−05 |
| KEGG pathway | ||||
| 1 | hsa04668 | TNF signaling pathway | 4 of 108 | 1.27e−05 |
| 2 | hsa04064 | NF-kappa B signaling pathway | 4 of 93 | 1.27e−05 |
| 3 | hsa05160 | Hepatitis C | 4 of 131 | 1.60e−05 |
| 4 | hsa04210 | Apoptosis | 4 of 135 | 1.60e−05 |
| 5 | hsa05167 | Kaposi's sarcoma-associated herpesvirus infection | 4 of 183 | 3.53e−05 |
| Reactome pathways | ||||
| 1 | HSA-5357956 | TNFR1-induced NFkappaB signaling pathway | 9 of 30 | 3.98e−21 |
| 2 | HSA-5357905 | Regulation of TNFR1 signaling | 9 of 32 | 3.98e−21 |
| 3 | HSA-5689880 | Ub-specific processing proteases | 10 of 202 | 1.94e−17 |
| 4 | HSA-6804757 | Regulation of TP53 Degradation | 7 of 35 | 2.30e−15 |
| 5 | HSA-5675482 | Regulation of necroptotic cell death | 6 of 17 | 2.63e−14 |
| UniPort keywords | ||||
| 1 | KW-0832 | Ubl conjugation | 9 of 2380 | 1.28e−05 |
| 2 | KW-0013 | ADP-ribosylation | 4 of 100 | 1.28e−05 |
| 3 | KW-1017 | Isopeptide bond | 7 of 1713 | 0.00017 |
| 4 | KW-0945 | Host–virus interaction | 4 of 432 | 0.00094 |
| 5 | KW-0963 | Cytoplasm | 9 of 4972 | 0.0015 |
| PFAM Protein Domains | ||||
| 1 | PF14560 | Ubiquitin-like domain | 4 of 14 | 3.12e−09 |
| 2 | PF11976 | Ubiquitin-2 like Rad60 SUMO-like | 4 of 21 | 6.44e−09 |
| 3 | PF00240 | Ubiquitin family | 4 of 46 | 7.76e−08 |
| 4 | PF02201 | SWIB/MDM2 domain | 2 of 5 | 2.86e−05 |
| 5 | PF00641 | Zn-finger in Ran binding protein and others | 2 of 16 | 0.00017 |
| INTERPRO Protein Domains and Features | ||||
| 1 | IPR019956 | Ubiquitin | 4 of 12 | 1.83e−09 |
| 2 | IPR019954 | Ubiquitin conserved site | 4 of 10 | 1.83e−09 |
| 3 | IPR000626 | Ubiquitin domain | 4 of 57 | 3.14e−07 |
| 4 | IPR016495 | p53 negative regulator Mdm2/Mdm4 | 2 of 2 | 1.46e−05 |
| 5 | IPR029071 | Ubiquitin-like domain superfamily | 4 of 184 | 1.75e−05 |
| SMART Protein Domains | ||||
| 1 | SM00213 | Ubiquitin homologues | 4 of 45 | 6.77e−08 |
| 2 | SM00005 | DEATH domain, found in proteins involved in cell death | 2 of 27 | 0.00035 |
| 3 | SM00184 | Ring finger | 3 of 308 | 0.0012 |
Functional enrichment of p53.
Figure 6
Figure 7
Pulldown Strategy and Protein Interaction Prediction for Biomarker Selection
Pull-down assays serve as a complementary method to further validate the predicted interactions in a quantitative manner towards understanding their dissociation constants and relative bindings of proteins and their direct binding sites. However, this is beyond the scope of this study. We believe the following recommendations should be followed by researchers investigating transient protein interactions: First, determining the protein solubility is essential. If the prey protein is at a too-high concentration, it will not be sufficiently soluble. Second, shortening the time and adjusting buffer conditions of incubation help prevent prey protein degradation. Third, checking the prey protein with beads if bait protein is not bound should be done as a control. Fourth, conducting all assays at a constant temperature of 4 °C should be considered if a variation in Kd is found between repeated experiments.
The tumor suppressor antigen p53 depends on specific cellular conditions to induce arrest of cell growth and to control cell division (Pucci et al., 2000; Chen, 2016).
Our network analysis (entry N00170, class nt06164) showed involvement of LANA and other effector markers in KS conditions and helped elucidate their mechanisms of action (Figure 8, Table 4). Therefore, we suggest that ORF-73 is an important protein that may be a useful biomarker for AIDS-related KS. Studies have suggested a linkage between ORF-73 and host apoptosis through p53 signaling pathways (Tornesello et al., 2018), that could represent a molecular mechanism for the predicted markers associated with KS. Our study discovered KS-associated markers which trigger cancer. ORF-73 encodes LANA-1 virtual proteins of KSHV, linking them with AIDS-associated KS, by their interaction with several cellular processes which include cell apoptosis (through p53) and inhibition of downstream transcriptomic performance. The association between HIV and ORF73 can be inferred by these findings.
Figure 8
Table 4
| Sl. No | Entry | Description |
|---|---|---|
| 1 | N00216 | HGF-MET-RAS-ERK signaling pathway |
| 2 | N00160 | KSHV K1 to RAS-ERK signaling pathway |
| 3 | N00188 | IL1-IL1R-JNK signaling pathway |
| 4 | N00189 | KSHV K15 to JNK signaling pathway |
| 5 | N00186 | IL1-IL1R-p38 signaling pathway |
| 6 | N00187 | KSHV Kaposin B to p38 signaling pathway |
| 7 | N00182 | IGF-IGFR-PI3K-NFKB signaling pathway |
| 8 | N00179 | KSHV K1 to PI3K-NFKB signaling pathway |
| 9 | N00030 | EGF-EGFR-RAS-PI3K signaling pathway |
| 10 | N00159 | KSHV K1 to PI3K signaling pathway |
| 11 | N00056 | Wnt signaling pathway |
| 12 | N00175 | KSHV LANA to Wnt signaling pathway |
| 13 | N00053 | Cytokine-Jak-STAT signaling pathway |
| 14 | N00181 | KSHV vIL-6 to Jak-STAT signaling pathway |
| 15 | N00147 | EGF-EGFR-PLCG-calcineurin signaling pathway |
| 16 | N00180 | KSHV K1 to PLCG-calcineurin signaling pathway |
| 17 | N00172 | KSHV K15 to PLCG-calcineurin signaling pathway |
| 18 | N00148 | TLR3-IRF7 signaling pathway |
| 19 | N00162 | KSHV vIRF3 to TLR3-IRF7 signaling pathway |
| 20 | N00163 | KSHV KIE1/2 to TLR3-IRF7 signaling pathway |
| 21 | N00149 | TLR3-IRF3 signaling pathway |
| 22 | N00161 | KSHV vIRF1/2 to TLR3-IRF3 signaling pathway |
| 23 | N00463 | Alternative pathway of complement activation |
| 24 | N00213 | KSHV Kaposin to alternative pathway of complement activation |
| 25 | N00150 | Type I IFN signaling pathway |
| 26 | N00261 | KSHV vIRF2 to IFN signaling pathway |
| 27 | N00151 | TNF-NFKB signaling pathway |
| 28 | N00174 | KSHV vFLIP to TNF-NFKB signaling pathway |
| 29 | N00173 | KSHV K15 to TNF-NFKB signaling pathway |
| 30 | N00171 | KSHV vFLIP to NFKB signaling pathway |
| 31 | N00152 | CXCR-GNB/G-ERK signaling pathway |
| 32 | N00157 | KSHV vGPCR to GNB/G-ERK signaling pathway |
| 33 | N00153 | CCR/CXCR-GNB/G-PI3K-RAC signaling pathway |
| 34 | N00462 | KSHV vCCL1/2/3 to CCR signaling pathway |
| 35 | N00212 | KSHV vCCL2 to CCR signaling pathway |
| 36 | N00178 | KSHV vGPCR to GNB/G-PI3K-JNK signaling pathway |
| 37 | N00154 | CXCR-GNB/G-PI3K-AKT signaling pathway |
| 38 | N00158 | KSHV vGPCR to GNB/G-PI3K-AKT signaling pathway |
| 39 | N00363 | Antigen processing and presentation by MHC class I molecules |
| 40 | N00184 | KSHV MIR1/2 to antigen processing and presentation by MHC class I molecules |
| 41 | N00185 | KSHV MIR2 to cell surface molecule-endocytosis |
| 42 | N00155 | Autophagy-vesicle nucleation |
| 43 | N00177 | KSHV vBCL2 to autophagy-vesicle nucleation |
| 44 | N00156 | Autophagy-vesicle elongation |
| 45 | N00176 | KSHV vFLIP to autophagy-vesicle elongation |
| 46 | N00066 | MDM2-p21-Cell cycle G1/S |
| 47 | N00167 | KSHV vIRF1/3 to p21-cell cycle G1/S |
| 48 | N00169 | KSHV LANA to p21-cell cycle G1/S |
| 49 | N00168 | KSHV vCyclin to cell cycle G1/S |
| 50 | N00170 | KSHV LANA to cell cycle G1/S |
| 51 | N00146 | Crosstalk between extrinsic and intrinsic apoptotic pathways |
| 52 | N00166 | KSHV vFLIP to crosstalk between extrinsic and intrinsic apoptotic pathways |
| 53 | N00164 | KSHV vBCL2 to crosstalk between extrinsic and intrinsic apoptotic pathways |
| 54 | N00165 | KSHV vIAP to crosstalk between extrinsic and intrinsic apoptotic pathways |
Identities of associated markers, downstream signaling candidates, and linked pathways during Kaposi sarcoma pathogenesis.
Discussion
Many viral genes are homologous to host cellular genes in KSHV (Swanton et al., 1997). The PubMed, Google Scholar, and Scopus searches confirmed the key diagnostic markers for KS based on the available literature. Our computational study on them revealed their importance and evolutionary role in human cancer biology. LANA-1 imparts important immunogenic effects to KSHV, and it specifically interacts with many cellular pathways, including that of cell apoptosis (through its interaction with p53, and repression of downstream transcripts; see Table 4). This induces oncogenesis by targeting the protein-E2F transcriptional regulatory pathway (Radkov et al., 2000). The protein homologues identified through our search were structurally different from each other. Therefore, we analyzed selected proteins and compared them using homology searches for the selected domains to prove interactions with other host proteins that trigger and induce cancer in individuals with immunosuppression (Kersse et al., 2011). Hyper mutation and conserved structural sequence similarities help to maintain key aspects of secondary and tertiary structures, which were consistent with the computational analyses in our study (Huang et al., 2002). Figure 5 shows the KSHV infection pathway from KEGG. We highlighted the reference pathway using a red box that shows that LANA is associated with the p53 signaling pathway. A BLAST homology search confirmed an ORF-73 marker interaction during herpesvirus pathogenesis. The results of STRING and KEGG searches suggested ORF-73 interacts with the host p53.
ORF-73 is not the only protein marker implicated in KS pathology, but much about it remains unknown. It is used as a marker for KSHV; especially, its protein folding and motifs are important for the marker assessment observed in the pattern of structural domains in the selected sequence analyzed with PSI-PRED. The pathogenic interactions in the network-based analysis between LANA and the host p53 suggest that LANA was confirmed by STRING and FUGUE tools. The predicted sequence motifs give detailed interactions that are conserved in the subfamilies of the herpesviruses as discussed in detail on the KEGG pathway with notable mechanisms described in the literature (Schulz, 2000; Direkze and Laman, 2004; Sharma-Walia et al., 2004; Mesri et al., 2010). However, the markers associated with KS need to be incorporated into comprehensive clinical cohort studies, designed using differential protein purification techniques and evidence-based knowledge on protein interactions with bait proteins to develop practical medical applications in the future.
Many PPIs have been elucidated using pull-down assays to map the genomes of many organisms, such as yeast (Valente et al., 2009), Escherichia coli (Arifuzzaman et al., 2006) Caenorhabditis elegans (Remmelzwaal and Boxem, 2019).
Like all other herpesviruses, KSHV displays latency and a lytic life cycle replication that are characteristic of some viral gene expressions. The genes LANA, v-FLIP, v-cyclin, and Kaposins A, B, and C for latency facilitate the establishment of life in its host and survival against host immune mechanisms. During latency, proteins expressed as K1, K15, vIL6, vGPCR, vIRFs, and vCCLs participate in inflammatory and angiogenic processes evident in KS lesions. Many other lytic and latent viral proteins are involved in the transformation of KSHV host cells into malignant cells. Also, Bcl-2 is one of the major KS progression factors, and TP53 and c-myc have a role in the progression of disease. KS pathology is interconnected with immune modulation effects such as cell cycle arrest in the host cell, which is required for pathogenic conditions and is mitigated by modulating key factors such as LANA.
Likewise, measuring the expression level and identifying the function of the encoded protein products is important to understand the pathogenesis of KS. We used a methodology similar to that in co-immunoprecipitation (Co-IP) experiments because of our ligand's affinity to capture the strongest interacting proteins (Lapetina and Gil-Henn, 2017). MS identifies subunits and helps explore the structural information associated with the protein of interest (Byrum et al., 2012). Dynamic PPI machines assemble or disassemble the ever-changing inter-, intra-, and extracellular influx cues as a preliminary step towards understanding the structure of proteins and to determine their functions to identify the relevant pathways of interacting proteins (Einarson, 2001; Vikis and Guan, 2004; Einarson et al., 2007). The role and important reason to select ORF-73 in the study is that encoding LANA protein distinct domain induces a putative nuclear localization signal (NLS), which product shown interacting with many co-cellular p53, pRb, and ATF4/CREB2. LANA also modulates transcriptional activity of HIV-1 long terminal repeat and to understand the how ORF-73 appears to prevent activity of KS-associated genes was new to know to make preventive strategy (Schäfer et al., 2003). Our findings may help researchers planning cancer prevention strategies, but we used common computational analyses alone, and future studies with expression and interaction analyses should be used to confirm our results and generate treatment options for KS.
Conclusion
Our computational studies found that ORF-73 is involved in host apoptosis through p53 signaling pathways and is a key marker associated for Kaposi Sarcoma. This study also identified potential KS-associated genes which are reported to trigger cancer and suggested mechanisms of interaction that may help researcher developing prevention strategies.
Funding
This study was supported by the Seed Fund Program of Shanghai University of Medicine and Health Sciences (Grant No. SFP-18-21-01-002), the General Program of Pudong New Area Health and Family Planning Commission of Shanghai, China (Grant No. PW2016A-7), the National Natural Science Foundation of China (No. 81830052), Construction project of Shanghai Key Laboratory of Molecular Imaging (18DZ2260400), Shanghai Municipal Education Commission (Class II Plateau Disciplinary Construction Program for Medical Technology of SUMHS, 2018-2020), and the Natural Science Foundation of Guangdong Province (2016A030313680).
Statements
Ethics statement
We retrieved all data from publicly available resources and we required no ethical approvals for dissemination of this purely academic information.
Author contributions
PZ, JW, and XZ conceived and designed the study. XW, LJ and XG provided study materials and were responsible for the collection and assembly of data, data analysis, and interpretation. PZ was involved in writing of the manuscript. All authors read and approved the final manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2019.01376/full#supplementary-material
Supplementary Figure 1Flow chart showing the methodology for choosing selective markers for downstream analyses to develop a PPI network.
References
1
AkaP. V.KempT. J.RabkinC. S.ShielsM. S.PolizzottoM. N.LauriaC.et al. (2015). A multiplex panel of plasma markers of immunity and inflammation in classical kaposi sarcoma. J. Infect. Dis.211, 226–229. doi: 10.1093/infdis/jiu410
2
ArifuzzamanM.MaedaM.ItohA.NishikataK.TakitaC.SaitoR.et al. (2006). Large-scale identification of protein-protein interaction of Escherichia coli K-12. Genome Res.16, 686–691. doi: 10.1101/gr.4527806
3
Barré-SinoussiF.ChermannJ. C.ReyF.NugeyreM. T.ChamaretS.GruestJ.et al. (1983). Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science220, 868–871. doi: 10.1126/science.6189183
4
BeralV.PetermanT. A.BerkelmanR. L.JaffeH. W. (1990). Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet335, 123–128. doi: 10.1016/0140-6736(90)90001-l
5
BhutaniM.PolizzottoM. N.UldrickT. S.YarchoanR. (2015). Kaposi sarcoma-associated herpesvirus-associated malignancies: epidemiology, pathogenesis, and advances in treatment. Semin. Oncol.42, 223–246. doi: 10.1053/j.seminoncol.2014.12.027
6
BujnickiJ. M.RychlewskiL. (2001). The herpesvirus alkaline exonuclease belongs to the restriction endonuclease PD-(D/E)XK superfamily: insight from molecular modeling and phylogenetic analysis. Virus Genes22, 219–230. doi: 10.1023/A:1008131810233
7
ByrumS.SmartS. K.LarsonS.TackettA. J. (2012). Analysis of stable and transient protein-protein interactions. Methods Mol. Biol.833, 143–152. doi: 10.1007/978-1-61779-477-3_10
8
ChangY.CesarmanE.PessinM. S.LeeF.CulpepperJ.KnowlesD. M.et al. (1994). Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science266, 1865–1869. doi: 10.1126/science.7997879
9
ChenJ. (2016). The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring HarbPerspect Med.6, a026104. doi: 10.1101/cshperspect.a026104
10
CiufoD. M.CannonJ. S.PooleL. J.WuF. Y.MurrayP.AmbinderR. F.et al. (2001). Spindle cell conversion by Kaposi's sarcoma-associated herpesvirus: formation of colonies and plaques with mixed lytic and latent gene expression in infected primary dermal microvascular endothelial cell cultures. J. Virol.75, 5614–5626. doi: 10.1128/JVI.75.12.5614-5626.2001
11
CottoniF.MasalaM. V.SantarelliR.CarcassiC.UcciniS.MontesuM. A.et al. (2004). Susceptibility to human herpesvirus-8 infection in a healthy population from Sardinia is not directly correlated with the expression of HLA-DR alleles. Br. J. Dermatol.151, 247–249. doi: 10.1111/j.1365-2133.2004.06060.x
12
DelgadoT.CarrollP. A.PunjabiA. S.MargineantuD.HockenberyD. M.LagunoffM. (2010). Induction of the Warburg effect by Kaposi's sarcoma herpesvirus is required for the maintenance of latently infected endothelial cells. Proc. Natl. Acad. Sci. U.S.A.107, 10696–10701. doi: 10.1073/pnas.1004882107
13
Della BellaS.TaddeoA.CalabròM. L.BrambillaL.BellinviaM.BergamoE.et al. (2008). Peripheral blood endothelial progenitors as potential reservoirs of Kaposi's sarcoma-associated herpesvirus. PloS One3, e1520. doi: 10.1371/journal.pone.0001520
14
DirekzeS.LamanH. (2004). Regulation of growth signalling and cell cycle by Kaposi's sarcoma-associated herpesvirus genes. Int. J. Exp. Pathol.85, 305–319. doi: 10.1111/j.0959-9673.2004.00407.x
15
DittmerD. P.DamaniaB. (2019). “Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Associated Disease in the AIDS Patient: An Update,” in HIV/AIDS-Associated Viral Oncogenesis (Cham: Springer), 63–80.
16
DorakM. T.YeeL. J.TangJ.ShaoW.LobashevskyE. S.JacobsonL. P.et al. (2005). HLA-B, -DRB1/3/4/5, and -DQB1 gene polymorphisms in human immunodeficiency virus-related Kaposi's sarcoma. J. Med. Virol.76, 302–310. doi: 10.1002/jmv.20361
17
DuusK. M.LentchitskyV.WagenaarT.GroseC.Webster-CyriaqueJ. (2004). Wild-type Kaposi's sarcoma-associated herpesvirus isolated from the oropharynx of immune-competent individuals has tropism for cultured oral epithelial cells. J. Virol.78, 4074–4084. doi: 10.1128/jvi.78.8.4074-4084.2004
18
EinarsonM. B.PugachevaE. N.OrlinickJ. R. (2007). Identification of protein-protein interactions with glutathione-S-Transferase (GST) fusion proteins. CSH Protoc.2007. doi: 10.1101/pdb.top11
19
EinarsonM. (2001). “Detection of Protein-Protein Interactions Using the GST Q21 Fusion Protein Pulldown Technique,” in Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Protocols, 2006(1).
20
EnsserA.GlykofrydesD.NiphuisH.KuhnE. M.RosenwirthB.HeeneyJ. L.et al. (2001). Independence of herpesvirus-induced T cell lymphoma from viral cyclin D homologue. J. Exp. Med.193, 637–642. doi: 10.1084/jem.193.5.637
21
FickenscherH.BiesingerB.KnappeA.WittmannS.FleckensteinB. (1996). Regulation of the herpesvirus saimiri oncogene stpC, similar to that of T-cell activation genes, in growth-transformed human T lymphocytes. J. Virol.70, 6012–6019.
22
FloreO.RafiiS.ElyS.O'LearyJ. J.HyjekE. M.CesarmanE. (1998). Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus. Nature394, 588–592. doi: 10.1038/29093
23
FranceschiniA.SzklarczykD.FrankildS.KuhnM.SimonovicM.RothA.et al. (2013). STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res.41, D808–D815. doi: 10.1093/nar/gks1094
24
FukunagaM. (2005). Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumours. Histopathology46, 396–402. doi: 10.1111/j.1365-2559.2005.02098.x
25
GalloR. C. (1998). The enigmas of Kaposi's sarcoma. Science282, 1837–1839. doi: 10.1126/science.282.5395.1837
26
GaurN.TiklaT.KaulR. (2019). Kaposi sarcoma-associated herpes virus (KSHV) latent protein LANA modulates cellular genes associated with epithelial-to-mesenchymal transition. Arch. Virol.164 (1), 91–104. doi: 10.1007/s00705-018-4060-y
27
GazouliM.ZavosG.PapaconstantinouI.LukasJ. C.ZografidisA.BoletisJ.et al. (2004). The interleukin-6-174 promoter polymorphism is associated with a risk of development of Kaposi's sarcoma in renal transplant recipients. Anticancer Res.24, 1311–1314.
28
GelmannE. P.PopovicM.BlayneyD.MasurH.SidhuG.StahlR. E.et al. (1983). Proviral DNA of a retrovirus, human T-cell leukemia virus, in two patients with AIDS. Science220, 862–865. doi: 10.1126/science.6601822
29
GlykofrydesD.NiphuisH.KuhnE. M.RosenwirthB.HeeneyJ. L.BruderJ.et al. (2000). Herpesvirus saimiri vFLIP provides an antiapoptotic function but is not essential for viral replication, transformation, or pathogenicity. J. Virol.74, 11919–11927. doi: 10.1128/jvi.74.24.11919-11927.2000
30
GregoryS. M.DavisB. K.WestJ. A.TaxmanD. J.MatsuzawaS.ReedJ. C.et al. (2011). Discovery of a viral NLR homolog that inhibits the inflammasome. Science331, 330–334. doi: 10.1126/science.1199478
31
HouC.WangF.LiuX.ChangG.WangF.GengX. (2017). Comprehensive analysis of interaction networks of telomerase reverse transcriptase with multiple bioinformatic approaches: deep mining the potential functions of telomere and telomerase. Rejuvenation Res.20, 320–333. doi: 10.1089/rej.2016.1909
32
HuangQ.PetrosA. M.VirginH. W.FesikS. W.OlejniczakE. T. (2002). Solution structure of a Bcl-2 homolog from Kaposi sarcoma virus. Proc. Natl. Acad. Sci. U.S.A.99, 3428–3433. doi: 10.1073/pnas.062525799
33
HuntS.Santa CruzD.BarnhillR. (2004). Vascular tumors.
34
JonesD. T.CozzettoD. (2015). DISOPRED3: precise disordered region predictions with annotated protein-binding activity. Bioinformatics31, 857–863. doi: 10.1093/bioinformatics/btu744
35
JonesD. T. (1999). Protein secondary structure prediction based on position-specific scoring matrices. J. Mol. Biol.292, 195–202. doi: 10.1006/jmbi.1999.3091
36
KanashiroC. A.SchallyA. V.GrootK.ArmatisP.BernardinoA. L. F.VargaJ. L. (2003). Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. Proc. Natl. Acad. Sci. U.S.A.100, 15836–15841. doi: 10.1073/pnas.2536558100
37
Kaposi (1872). Idiopathisches multiples Pigmentsarkom der Haut. Arch. f. Dermat.4, 265–273. doi: 10.1007/BF01830024
38
KersseK.VerspurtenJ.Vanden BergheT.VandenabeeleP. (2011). The death-fold superfamily of homotypic interaction motifs. Trends Biochem. Sci.36, 541–552. doi: 10.1016/j.tibs.2011.06.006
39
La FerlaL.PinzoneM. R.NunnariG.MartellottaF.LleshiA.TirelliU.et al. (2013). Kaposi' s sarcoma in HIV-positive patients: the state of art in the HAART-era. Eur. Rev. Med. Pharmacol. Sci.17, 2354–2365.
40
LapetinaS.Gil-HennH. (2017). A guide to simple, direct, and quantitative in vitro binding assays. J. Biol. Methods4, e62. doi: 10.14440/jbm.2017.161
41
LiangC.LeeJ.-S.JungJ. U. (2008). Immune evasion in Kaposi's sarcoma-associated herpes virus associated oncogenesis. Semin. Cancer Biol.18, 423–436. doi: 10.1016/j.semcancer.2008.09.003
42
MajerciakV.PripuzovaN.ChanC.TemkinN.SpechtS. I.ZhengZ.-M. (2015). Stability of structured Kaposi's sarcoma-associated herpesvirus ORF57 protein is regulated by protein phosphorylation and homodimerization. J. Virol.89, 3256–3274. doi: 10.1128/JVI.03721-14
43
MartinJ. N.GanemD. E.OsmondD. H.Page-ShaferK. A.MacraeD.KedesD. H. (1998). Sexual transmission and the natural history of human herpesvirus 8 infection. N. Engl. J. Med.338, 948–954. doi: 10.1056/NEJM199804023381403
44
MesriE. A.CesarmanE.BoshoffC. (2010). Kaposi's sarcoma and its associated herpesvirus. Nat. Rev. Cancer10, 707–719. doi: 10.1038/nrc2888
45
MosesA. V.FishK. N.RuhlR.SmithP. P.StrussenbergJ. G.ZhuL.et al. (1999). Long-term infection and transformation of dermal microvascular endothelial cells by human herpesvirus 8. J. Virol.73, 6892–6902.
46
NguyenH. Q.MagaretA. S.KitahataM. M.Van RompaeyS. E.WaldA.CasperC. (2008). Persistent Kaposi sarcoma in the era of HAART: characterizing the predictors of clinical response. AIDS22, 937–945. doi: 10.1097/QAD.0b013e3282ff6275
47
ParkinD. M. (2006). The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer118, 3030–3044. doi: 10.1002/ijc.21731
48
PucciB.KastenM.GiordanoA. (2000). Cell cycle and apoptosis. Neoplasia2, 291–299. doi: 10.1038/sj.neo.7900101
49
RadkovS. A.KellamP.BoshoffC. (2000). The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat. Med.6, 1121–1127. doi: 10.1038/80459
50
RemmelzwaalS.BoxemM. (2019). Protein interactome mapping in Caenorhabditiselegans. Curr. Opin. Syst. Biol.13, 1–9. doi: 10.1016/j.coisb.2018.08.006
51
RoizmanB.CarmichaelL. E.DeinhardtF.de-TheG.NahmiasA. J.PlowrightW.et al. (1981). Herpesviridae. definition, provisional nomenclature, and taxonomy. The Herpesvirus study group, the international committee on taxonomy of viruses. Intervirology16, 201–217. doi: 10.1159/000149269
52
RussoJ. J.BohenzkyR. A.ChienM.-C.ChenJ.YanM.MaddalenaD.et al. (1996). Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). PNAS93, 14862–14867. doi: 10.1073/pnas.93.25.14862
53
SchäferA.LengenfelderD.GrillhöslC.WieserC.FleckensteinB.EnsserA. (2003). The latency-associated nuclear antigen homolog of herpesvirus saimiri inhibits lytic virus replication. J. Virol.77, 5911–5925. doi: 10.1128/jvi.77.10.5911-5925.2003
54
SchulzT. F. (2000). Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8): epidemiology and pathogenesis. J. Antimicrob. Chemother.45 Suppl T3, 15–27. doi: 10.1093/jac/45.suppl_4.15
55
Sharma-WaliaN.NaranattP. P.KrishnanH. H.ZengL.ChandranB. (2004). Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 envelope glycoprotein gB induces the integrin-dependent focal adhesion kinase-Src-phosphatidylinositol 3-kinase-rho GTPase signal pathways and cytoskeletal rearrangements. J. Virol.78, 4207–4223. doi: 10.1128/jvi.78.8.4207-4223.2004
56
ShiJ.BlundellT. L.MizuguchiK. (2001). FUGUE: sequence-structure homology recognition using environment-specific substitution tables and structure-dependent gap penalties. J. Mol. Biol.310, 243–257. doi: 10.1006/jmbi.2001.4762
57
SinfieldR. L.MolyneuxE. M.BandaK.BorgsteinE.BroadheadR.HesselingP.et al. (2007). Spectrum and presentation of pediatric malignancies in the HIV era: experience from Blantyre, Malawi, 1998-2003. Pediatr. Blood Cancer48, 515–520. doi: 10.1002/pbc.20917
58
SwantonC.MannD. J.FleckensteinB.NeipelF.PetersG.JonesN. (1997). Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature390, 184–187. doi: 10.1038/36606
59
TangS.LiT.CongP.XiongW.WangZ.SunJ. (2013). PlantLoc: an accurate web server for predicting plant protein subcellular localization by substantiality motif. Nucleic Acids Res.41, W441–W447. doi: 10.1093/nar/gkt428
60
ThomeM.SchneiderP.HofmannK.FickenscherH.MeinlE.NeipelF.et al. (1997). Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature386, 517–521. doi: 10.1038/386517a0
61
TorneselloM. L.AnnunziataC.TorneselloA. L.BuonaguroL.BuonaguroF. M. (2018). Human Oncoviruses and p53 Tumor Suppressor Pathway Deregulation at the Origin of Human Cancers. Cancers (Basel)10. doi: 10.3390/cancers10070213
62
ValenteA. X. C. N.RobertsS. B.BuckG. A.GaoY. (2009). Functional organization of the yeast proteome by a yeast interactome map. Proc. Natl. Acad. Sci. U.S.A.106, 1490–1495. doi: 10.1073/pnas.0808624106
63
VikisH. G.GuanK.-L. (2004). Glutathione-S-transferase-fusion based assays for studying protein-protein interactions. Methods Mol. Biol.261, 175–186. doi: 10.1385/1-59259-762-9:175
64
WassM. N.KelleyL. A.SternbergM. J. E. (2010). 3DLigandSite: predicting ligand-binding sites using similar structures. Nucleic Acids Res.38, W469–W473. doi: 10.1093/nar/gkq406
65
WeedenD. (2002). Vascular tumor In Skin Pathology.
66
WoodberryT.SuscovichT. J.HenryL. M.MartinJ. N.DollardS.O'ConnorP. G.et al. (2005). Impact of Kaposi sarcoma-associated herpesvirus (KSHV) burden and HIV coinfection on the detection of T cell responses to KSHV ORF73 and ORF65 proteins. J. Infect. Dis.192, 622–629. doi: 10.1086/432103
67
YanQ.LiW.TangQ.YaoS.LvZ.FengN.et al. (2013). Cellular microRNAs 498 and 320d regulate herpes simplex virus 1 induction of Kaposi's sarcoma-associated herpesvirus lytic replication by targeting RTA. PloS One8, e55832. doi: 10.1371/journal.pone.0055832
68
YarchoanR.UldrickT.PolizzottoM. (2015). “117 - HIV-associated malignancies,” in DeVita, Hellman, and Rosenberg"s Cancer: Principles and Practice of Oncology. Lippincott Williams and Wilkins.
69
Yee-LinV.Pooi-FongW.Soo-BengA. K. (2018). Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment. Mini Rev Med Chem18, 173–183. doi: 10.2174/1389557517666170717125821
70
ZhuF. X.ChongJ. M.WuL.YuanY. (2005). Virion proteins of Kaposi's sarcoma-associated herpesvirus. J. Virol.79, 800–811. doi: 10.1128/JVI.79.2.800-811.2005
71
zur HausenH. (2001). Oncogenic DNA viruses. Oncogene20, 7820–7823. doi: 10.1038/sj.onc.1204958
Summary
Keywords
herpesvirus, immune evasion, sequence homology, protein–protein interactions, AIDS, ORF-73
Citation
Zhang P, Wang J, Zhang X, Wang X, Jiang L and Gu X (2020) Identification of AIDS-Associated Kaposi Sarcoma: A Functional Genomics Approach. Front. Genet. 10:1376. doi: 10.3389/fgene.2019.01376
Received
03 September 2019
Accepted
17 December 2019
Published
24 January 2020
Volume
10 - 2019
Edited by
Quan Zou, University of Electronic Science and Technology of China, China
Reviewed by
Chenqi Wang, University of South Florida, United States; Biju Issac, Leidos Biomedical Research, Inc., United States; Lei Chen, Shanghai Maritime University, China
Updates
Copyright
© 2020 Zhang, Wang, Zhang, Wang, Jiang and Gu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xuefeng Gu, guxf@sumhs.edu.cn
†These authors have contributed equally to this work
This article was submitted to Bioinformatics and Computational Biology, a section of the journal Frontiers in Genetics
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.